What is the maximum daily dose of pregabalin for post‑herpetic neuralgia?

Maximum Dose of Pregabalin for Postherpetic Neuralgia

The maximum dose of pregabalin for postherpetic neuralgia is 600 mg/day, administered as either 300 mg twice daily or 200 mg three times daily.

FDA-Approved Dosing

The FDA label explicitly states that for postherpetic neuralgia, pregabalin dosing should be 1:

• Starting dose: 75 mg twice daily or 50 mg three times daily (150 mg/day)
• Initial titration: Increase to 300 mg/day within 1 week based on efficacy and tolerability
• Maximum dose: 300 mg twice daily or 200 mg three times daily (600 mg/day total)

For patients who do not achieve sufficient pain relief after 2-4 weeks on 300 mg/day and who tolerate the medication well, the dose may be increased to the maximum of 600 mg/day 1.

Clinical Guideline Recommendations

The Mayo Clinic neuropathic pain management guidelines align with FDA labeling, confirming that 2:

• Maximum dosage: 600 mg/day (200 mg three times daily or 300 mg twice daily)
• Dose adjustment required in renal impairment
• Duration of adequate trial: 4 weeks

Important Clinical Considerations

Efficacy vs. Tolerability Trade-off

Higher doses are not consistently more effective than 300 mg/day but are associated with greater adverse effects 2. The guidelines note that while 600 mg/day can be used, it should be reserved for patients who:

1. Have ongoing pain despite 300 mg/day
2. Tolerate 300 mg/day without dose-limiting side effects
3. Have been on 300 mg/day for 2-4 weeks without adequate relief

Evidence from Clinical Trials

Research demonstrates dose-dependent efficacy in postherpetic neuralgia 3:

• 300 mg/day: 50% of patients achieved ≥30% pain reduction (vs. 25% placebo); NNTB 3.9
• 600 mg/day: 62% of patients achieved ≥30% pain reduction (vs. 24% placebo); NNTB 2.7

However, adverse events also increase dose-dependently 3:

• Somnolence: 16% at 300 mg/day vs. 25% at 600 mg/day
• Dizziness: 29% at 300 mg/day vs. 35% at 600 mg/day

Renal Dosing Adjustment

Critical caveat: The 600 mg/day maximum applies only to patients with creatinine clearance ≥60 mL/min 1. Patients with renal impairment require dose reduction based on creatinine clearance, which is particularly important since postherpetic neuralgia predominantly affects elderly patients who often have reduced renal function.

Practical Dosing Algorithm

1. Start at 150 mg/day (75 mg BID or 50 mg TID)
2. Increase to 300 mg/day after 3-7 days if tolerated
3. Maintain 300 mg/day for 2-4 weeks to assess response
4. If inadequate pain relief AND good tolerability, increase to 600 mg/day
5. Do not exceed 600 mg/day - no additional benefit and increased adverse effects

Doses above 600 mg/day are not recommended and provide no additional clinical benefit 2.